Genitourinary Cancers

Mature results from the phase III KEYNOTE-045 study presented at the 2017 ESMO Congress demonstrated that overall survival with pembrolizumab (Keytruda) continued to improve compared to chemotherapy in patients with recurrent, advanced urothelial carcinoma.

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the significance of the phase II CABOSUN trial, which explored cabozantinib (Cabometyx) as a frontline therapy for patients with renal cell carcinoma (RCC).

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the goals of the newly updated guidelines in renal cell carcinoma.

Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses the importance of multidisciplinary care in prostate cancer.

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses combinations with immunotherapy being investigated for patients with kidney cancer.

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses the CABOSUN trial investigating cabozantinib (Cabometyx) and sunitinib (Sutent) in patients with renal cell carcinoma (RCC).

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses a study of active surveillance in younger men with prostate cancer.

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of referring patients to clinical trials in bladder cancer.

Ketan K. Badani, MD, professor of urology at Mount Sinai Hospital, discusses how to determine which patient with renal cell carcinoma (RCC) will benefit from robotic surgery.

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the importance of understanding novel agents such as immunotherapeutic across disciplines in the treatment of genitourinary malignancies.

The European Commission has approved pembrolizumab (Keytruda) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy, or who are not eligible for cisplatin-containing chemotherapy.

Jihad Kaouk, MD, urologist, Cleveland Clinic, discusses the benefits of robotic partial nephrectomy for patients with renal cell carcinoma (RCC).

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses recent advancements in the management of kidney cancer.